PARTNERING
As an emerging biotechnology company, Transition is forging collaborations and licensing agreements with other biotech and pharmaceutical companies as an important part of its drug-development strategy.
Transition is open to discuss any licensing/collaboration opportunities for our products, as well as potential partnerships that may be of mutual interest. Please contact:
Contact information
Transition is open to discuss any licensing/collaboration opportunities for our products, as well as potential partnerships that may be of mutual interest. Please contact:
Contact information
Mr. Carl Damiani, MBA
Vice President, Business Development
T. 416.260.7770 ext. 206
E.
Vice President, Business Development
T. 416.260.7770 ext. 206
E.










